The National Medical Products Administration of China has approved the Covid-19 vaccine developed by Sinovac, the company said Saturday in a statement.
The vaccine is safe for people from 18 years of age and is to be applied in two doses of 0.5 milliliters each at an interval of between 14 and 28 days.
"The conditional marketing approval," the statement noted, "is based on the results of two months of overseas Phase 3 clinical trials. Definitive data have not yet been obtained, and efficacy and safety results require further confirmation."
Phase 3 clinical trials left different effectiveness rates for Sinovac's vaccine: while tests in Turkey showed 91.25 percent effectiveness, data from Indonesia showed 65.3 percent, and Brazil lowered the figure to 50.4 percent a week after announcing 78 percent.
In a statement issued this week, when Sinovac applied to the authorities for approval of the vaccine, the company said it has already been given "to tens of thousands of people in China as part of an emergency use program launched in July that targeted specific groups at high risk of infection."
It is the second vaccine to be approved after one developed by Sinopharm, which was authorized for public use on December 31.
China aims to inoculate 50 million people before the Lunar New Year on February 12, the country's most popular holiday, which sees large numbers of people travel. EFE-EPA